18.03.2021 • NewsAstraZenecaCOVID-19

EMA Gives All Clear for AstraZeneca Covid Shot

After a day’s deliberation, the European Medicines Agency (EMA) has decided that AstraZeneca’s Covid-19 vaccine is safe and effective and that potential side effects observed across the EU are not too great to run the risk of being infected with the virus.

EMA launched its review following moves by more than 12 EU member states to temporarily halt inoculations with the shot over fears it could lead to very rare cases of blood clots, in combination with thrombocytopenia (low levels of blood platelets).

The medicines agency said it found no batch issues or quality issues with the vaccine, although it was unable to definitively rule out a link with the blood clot incidents. The EMA plans to continue studying possible links between the blood clots and the vaccine and also will update its guidance for the vaccine to explain potential risks.

Some 30 cases of blood clots were reported in people who had received the vaccine originally developed by the University of Oxford in the UK. Some countries halted shots altogether, while others stopped using individual batches of the vaccine.

Before its review, the EMA recommended that EU countries continue vaccinations with the shot as did the World Health Organization. The discussion over the risks associated with the clots helped heat up the cold war between the UK and the EU. Brexit hardliners accused European officials of trying to sabotage the British-made vaccine in retaliation for Britain’s leaving the bloc.

Author: Dede Williams, Freelance Journalist

The European Medicines Agency (EMA) has decided that AstraZeneca’s Covid-19...
The European Medicines Agency (EMA) has decided that AstraZeneca’s Covid-19 vaccine is safe and effective and that potential side effects observed across the EU are not too great to run the risk of being infected with the virus that is gaining strength across Europe again. (c) AstraZeneca

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.